中文
关于我们
主营业务
技术平台
学术交流
新闻中心
加入我们
主营业务
表单填写
*姓名
*电话
*邮箱
*公司
*留言信息
熙宁小课-第181期 | FDA, OECD及CFDA (NMPA) GLP法规比较——系列12 档案
发布作者:熙宁生物发布时间:2025-07-25

CFDA

· 第十三条 档案保管的设施应当符合以下要求:

(一)防止未经授权批准的人员接触档案;

(二)计算机化的档案设施具备阻止未经授权访问和病毒防护等安全措施;

(三)根据档案贮藏条件的需要配备必要的设备,有效地控制火、水、虫、鼠、电力中断等危害因素;

(四)对于有特定环境条件调控要求的档案保管设施,进行充分的监测。


OECD

· Section II

3.4. Archive facilities should be provided for the secure storage and retrieval of study plans, raw data, final reports, samples of test items and specimens. Archive design and archive conditions should protect contents from untimely deterioration.

10.3 Only personnel authorised by management should have access to the archives. 


FDA

· 58.51

Space shall be provided for archives, limited to access by authorized personnel only, for the storage and retrieval of all raw data and specimens from completed studies.

· 58.190

(b) There shall be archives for orderly storage and expedient retrieval of all raw data, documentation, protocols, specimens, and interim and final reports. Conditions of storage shall minimize deterioration of the documents or specimens in accordance with the requirements for the time period of their retention and the nature of the documents or specimens. A testing facility may contract with commercial archives to provide a repository for all material to be retained. Raw data and specimens may be retained elsewhere provided that the archives have specific reference to those other locations.



均要求机构应有档案设施,但

· 

OECD要求由管理层授权进入档案室,而CFDA与FDA未指明由谁授权;

·  

CFDA要求对特定环境条件进行充分的监测,而OECD与FDA未提出明确要求;

·  

CFDA列出对计算机化的档案设施的要求,而OECD与FDA未提出明确要求;

·  

FDA此处有提及中期报告,而CFDA与OECD未出现过中期报告;

·  

FDA规定可以使用外包档案室;OECD   No.15 4.3部分规定可以使用外包档案室;CFDA未见外包档案室相关描述。





CFDA

· 第四十一条

专题负责人应当确保研究所有的资料,包括试验方案的原件、原始数据、标本、相关检测报告、留样受试物和对照品、总结报告的原件以及研究有关的各种文件,在研究实施过程中或者研究完成后及时归档,最长不超过两周,按标准操作规程的要求整理后,作为研究档案予以保存。


OECD

· Section II 10.1

The following should be retained in the archives for the period specified by the appropriate authorities:

a) The study plan, raw data, samples of test and reference items, specimens, and the final report of each study;


FDA

· 58.190 Storage and retrieval of records and data

(a) All raw data, documentation, protocols, final reports, and specimens (except those specimens obtained from mutagenicity tests and wet specimens of blood, urine, feces, and biological fluids) generated as a result of a nonclinical laboratory study shall be retained.



要求归档的材料基本一致,不一致之处:

· 

CFDA要求归档方案和报告的原件,而OECD与FDA并未要求原件;

· 

FDA列出了不需要归档的样本:致突变测试中获得的样本;血液、尿液、粪便和生物体液样本;

· 

CFDA要求归档相关检测报告,而OECD与FDA并未要求;

· 

CFDA与OECD要求归档留样受试物和对照品,而FDA未要求。但FDA 58.105章节(d)规定对于持续时间超过4周的项目,受试物和对照品的留样保留时间按照58.195章节规定执行;

· 

CFDA与FDA要求归档研究相关文件,OECD未要求;

· 

CFDA要求在研究实施过程中或者研究完成后及时归档,最长不超过两周;OECD与FDA的要求不同,参见系列7 SD的职责。




CFDA

· 第四十二条

研究被取消或者终止时,专题负责人应当将已经生成的上述研究资料作为研究档案予以保存归档。


OECD

-


FDA

-

· 

OECD在SD职责中有要求终止的项目应归档。

·  

FDA中未提及对终止项目的要求。




CFDA

· 第四十三条 

其他不属于研究档案范畴的资料,包括质量保证部门所有的检查记录及报告、主计划表、工作人员的教育背景、工作经历、培训情况、获准资质、岗位描述的资料、仪器设备及计算机化系统的相关资料、研究机构的人员组织结构文件、所有标准操作规程的历史版本文件、环境条件监测数据等,均应当定期归档保存。应当在标准操作规程中对具体的归档时限、负责人员提出明确要求。


OECD

· Section II 10.1 

b) Records of all inspections performed by the Quality Assurance Programme, as well as master schedules;

c) Records of qualifications, training, experience and job descriptions of personnel;

d) Records and reports of the maintenance and calibration of apparatus;

e) Validation documentation for computerised systems;

f) The historical file of all Standard Operating Procedures;

g) Environmental monitoring records.


FDA

· 58.195

(d) The master schedule sheet, copies of protocols, and records of quality assurance inspections, as required by 58.35(c) shall be maintained by the quality assurance unit as an easily accessible system of records for the period of time specified in paragraphs (a) and (b) of this section.

(e) Summaries of training and experience and job descriptions required to be maintained by 58.29(b) may be retained along with all other testing facility employment records for the length of time specified in paragraphs (a) and (b) of this section.

(f) Records and reports of the maintenance and calibration and inspection of equipment, as required by 58.63(b) and (c), shall be retained for the length of time specified in paragraph (b) of this section.

· 58.81

(d) A historical file of standard operating procedures, and all revisions thereof, including the dates of such revisions, shall be maintained.



需要保留的研究档案以外的资料基本一致,不同之处有:

·  

FDA要求QA相关的记录由质量保证部保留;

·  

FDA要求主计划表由质量保证部保留;

·  

FDA未对环境条件监测数据的保留进行规定;

·  

以上资料,CFDA要求定期归档;FDA和OECD要求归档。





CFDA

-


OECD

-


FDA

· 58.195

(g) Records required by this part may be retained either as original records or as true copies such as photocopies, microfilm, microfiche, or other accurate reproductions of the original records.


· 

FDA明确指出保留的文件可以是原件,也可以是真实副本。



CFDA

· 第四十四条

档案应当由机构负责人指定的专人按标准操作规程的要求进行管理,并对其完整性负责,同时应当建立档案索引以便于检索。进入档案设施的人员需获得授权。档案设施中放入或者取出材料应当准确记录。


OECD

· Section II

10.2 Material retained in the archives should be indexed so as to facilitate orderly storage and retrieval.

10.3 Only personnel authorised by management should have access to the archives. Movement of material in and out of the archives should be properly recorded. 


FDA

· 58.190

(c) An individual shall be identified as responsible for the archives. 

(d) Only authorized personnel shall enter the archives.

(e) Material retained or referred to in the archives shall be indexed to permit expedient retrieval. 



· 

要求一致

· 

OECD指出进入档案室的人员应获得管理层授权。



CFDA

· 第四十五条 档案的保存期限应当满足以下要求:

(一)用于注册申报材料的研究,其档案保存期应当在药物上市后至少五年;

(二)未用于注册申报材料的研究(如终止的研究),其档案保存期为总结报告批准日后至少五年;

(三)其他不属于研究档案范畴的资料应当在其生成后保存至少十年。


OECD

· Section II 10.1 

The following should be retained in the archives for the period specified by the appropriate authorities.


FDA

· 58.195

(a) Record retention requirements set forth in this section do not supersede the record retention requirements of any other regulations in this chapter. 

(b) Except as provided in paragraph (c) of this section, documentation records, raw data and specimens pertaining to a nonclinical laboratory study and required to be made by this part shall be retained in the archive(s) for whichever of the following periods is shortest: 

(1) A period of at least 2 years following the date on which an application for a research or marketing permit, in support of which the results of the nonclinical laboratory study were submitted, is approved by the Food and Drug Administration. This requirement does not apply to studies supporting investigational new drug applications (IND's) or applications for investigational device exemptions (IDE's), records of which shall be governed by the provisions of paragraph (b)(2) of this section. 

(2) A period of at least 5 years following the date on which the results of the nonclinical laboratory study are submitted to the Food and Drug Administration in support of an application for a research or marketing permit. 

(3) In other situations (e.g., where the nonclinical laboratory study does not result in the submission of the study in support of an application for a research or marketing permit), a period of at least 2 years following the date on which the study is completed, terminated, or discontinued.



·  

OECD并未对归档期限作出具体规定,而是要求根据相应的监管机构的要求。

·  

对于未用于注册、上市申请的项目,CFDA要求保存期限为报告批准后至少五年;而FDA要求至少两年。

·  

对于用于注册、上市申请的项目,CFDA要求药物上市后至少五年;而FDA进行了分类,部分要求批准后至少两年,部分要求(IND’s和IDE’s)提交后至少五年。

·  

非研究范畴的资料,CFDA规定应当在其生成后保存至少十年,其他未有规定。




_


CFDA

· 第四十六条 

档案保管期满时,可对档案采取包括销毁在内的必要处理,所采取的处理措施和过程应当按照标准操作规程进行,并有准确的记录。在可能的情况下,研究档案的处理应当得到委托方的同意。


OECD

· SectionII 10

In the absence of a required retention period, the final   disposition of any study materials should be documented.


FDA

-

· 

CFDA明确了档案期满后的处理要求,FDA并未有相关规定。OECD要求对任何项目材料的处置进行记录,处置方式应当是按照相关监管机构的要求。



CFDA

· 第四十七条 

对于质量容易变化的档案,如组织器官、电镜标本、血液涂片、受试物和对照品留样样品等,应当以能够进行有效评价为保存期限。对于电子数据,应当建立数据备份与恢复的标准操作规程,以确保其安全性、完整性和可读性,其保存期限应当符合本规范第四十五条的要求。


OECD

· Section II 10

When samples of test and reference items and specimens are   disposed of before the expiry of the required retention period for any   reason, this should be justified and documented. Samples of test and   reference items and specimens should be retained only as long as the quality   of the preparation permits evaluation.


FDA

· 58.195

(c) Wet specimens (except those specimens obtained from mutagenicity tests and wet specimens of blood, urine, feces, and biological fluids), samples of test or control articles, and specially prepared material, which are relatively fragile and differ markedly in stability and quality during storage, shall be retained only as long as the quality of the preparation affords evaluation. In no case shall retention be required for longer periods than those set forth in paragraphs (a) and (b) of this section.



· 

对于质量易发生变化的档案,保留时长要求是一致的,均要求不超过有效评价期。FDA也指出该保留期限同时不能超过项目其他材料的保存期限。

· 

CFDA中提出电子数据的保存规定要求且与纸质材料保存期限要求一致,而FDA与OECD No.1并未提及。

· 

OECD中描述了在有效期内进行的销毁应进行解释并记录。




CFDA

· 第四十八条

研究机构出于停业等原因不再执行本规范的要求、且没有合法的继承者时,其保管的档案应当转移到委托方的档案设施或者委托方指定的档案设施中进行保管,直至档案最终的保管期限。接收转移档案的档案设施应当严格执行本规范的要求,对其接收的档案进行有效的管理并接受监管部门的监督。


OECD

· Section II 10.4

If a test facility or an archive contracting facility goes out of business and has no legal successor, the archive should be transferred to the archives of the sponsor(s) of the study(s).


FDA

· 58.195

(h) If a facility conducting nonclinical testing goes out of business, all raw data, documentation, and other material specified in this section shall be transferred to the archives of the sponsor of the study. The Food and Drug Administration shall be notified in writing of such a transfer.



· 

CFDA与OECD要求没有合法继承者时,转移档案;FDA无继承者相关描述;

· 

OECD与FDA要求转移至委托方;CFDA要求转移至委托方或委托方指定的档案设施;

· 

FDA要求书面通知FDA.




欢迎各位同行进行勘误及指出不足之处。



参考文献:

[1] US FDA Good Laboratory Practice Regulations 21 CFR 58,effective June 20, 1979 and subsequent amendments

[2] OECD Principles of Good Laboratory Practice, as revised in 1997 and adopted November 26th, 1997 by decision of the OECD Council [C (97)186/Final]

[3] 国家食品药品监督管理总局,药物非临床研究质量管理规范,2017年9月1日生效



专属客服
免费通话
表单填写
回到顶部